ERBB2 and breast cancer: What is the quantitative association between pathologic complete response (pCR) and event-free survival (EFS) by intrinsic subtype and other gene expression signatures in patients with ERBB2/HER2-positive early breast cancer (EBC) treated in the neoadjuvant setting?